Biotec Services International completes its rebrand into PCI
9th February 2015, Bridgend, UK. PCI is pleased to announce that further to the acquisition in September 2014 of Biotec Services International, the company has today rebranded as part of the PCI group.
This rebrand brings together the expertise of two world class organizations and significantly expands PCI’s capability to deliver an integrated pharmaceutical service for global studies of investigational medicinal products.
The broad range of services includes manufacturing, packaging and labeling, QP and GMP consultancy, global distribution and returned drug management, as well as consultant services for optimal clinical package design, global logistics planning and depot management over a wide range of temperatures from controlled ambient to -196°C, a service for which Biotec is known across the globe.
Dr Fiona Withey, Managing Director, UK Clinical Services, stated, “The rebranding of Biotec demonstrates to the global pharmaceutical community that by joining the PCI group we are able to offer a significantly increased global capacity to deliver a worldwide offering to our clients across a wider range of services, while staying true to our core values of expertise, customer service, efficiency and flexibility. We are very excited about the investments PCI has undertaken of late, the acquisition of Biotec and Penn Pharma along with the construction of a new North American Storage, Distribution and Returns Management site, increases the breadth of the PCI service offering and provides our clients significant opportunity to engage with a truly global pharmaceutical services organization.”
Biotec recently announced the completion of an expansion to its Bridgend facilities. This development significantly expands the footprint of its clinical trial packaging and distribution services, as well as its Cold Chain expertise solutions - supporting medicines from +25°C down to -196°C. The enhanced Bridgend facilities are an important part of PCI’s network of sites encompassing both Europe and North America, providing clinical and commercial medicines to over 100 countries globally.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
